Tech-enabled clinical trial platform Paradigm announced its launch alongside a $203 million Series A funding round co-led by ARCH Venture Partners and General Catalyst.
F-Prime Capital, LUX Capital, GV, Magnetic Ventures and Mubadala Capital also participated in the round. American Cancer Society's BrightEdge fund was a strategic investor.
The company also announced its acquisition of Deep Lens...